<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Curr Oncol</journal-id><journal-id journal-id-type="publisher-id">CO</journal-id><journal-title-group><journal-title>Current Oncology</journal-title></journal-title-group><issn pub-type="ppub">1198-0052</issn><issn pub-type="epub">1718-7729</issn><publisher><publisher-name>Multimed Inc.</publisher-name><publisher-loc>66 Martin St. Milton, ON, Canada L9T 2R2</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20680106</article-id><article-id pub-id-type="pmc">2901795</article-id><article-id pub-id-type="publisher-id">conc-17-s31</article-id><article-categories><subj-group subj-group-type="heading"><subject>Medical Oncology</subject></subj-group></article-categories><title-group><article-title><italic>KRAS</italic> mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Souli&#x000e8;res</surname><given-names>D.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="af1-conc-17-s31">*</xref></contrib><contrib contrib-type="author"><name><surname>Greer</surname><given-names>W.</given-names></name><degrees>PhD, FCCMG</degrees><xref ref-type="aff" rid="af2-conc-17-s31">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Magliocco</surname><given-names>Anthony M.</given-names></name><degrees>MD, FRCPC FCAP</degrees><xref ref-type="aff" rid="af3-conc-17-s31">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Huntsman</surname><given-names>D.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="af4-conc-17-s31">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>S.</given-names></name><degrees>PhD, FCCMG, FACMG</degrees><xref ref-type="aff" rid="af4-conc-17-s31">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Tsao</surname><given-names>M.-S.</given-names></name><degrees>MD, FRCPC</degrees><xref ref-type="aff" rid="af5-conc-17-s31">||</xref></contrib><contrib contrib-type="author"><name><surname>Kamel-Reid</surname><given-names>S.</given-names></name><degrees>PhD, FACMG</degrees><xref ref-type="aff" rid="af5-conc-17-s31">||</xref><xref ref-type="corresp" rid="c1-conc-17-s31"/></contrib></contrib-group><aff id="af1-conc-17-s31"><label>*</label>Centre Hospitalier de l&#x02019;Universit&#x000e9; de Montr&#x000e9;al, Montreal, Quebec</aff><aff id="af2-conc-17-s31"><label>&#x02020;</label>Department of Pathology, Dalhousie University, Halifax, Nova Scotia</aff><aff id="af3-conc-17-s31"><label>&#x02021;</label>Departments of Oncology, Pathology and Laboratory Medicine, University of Calgary; Tom Baker Cancer Centre</aff><aff id="af4-conc-17-s31"><label>&#x000a7;</label>BC Cancer Agency, Vancouver, BC</aff><aff id="af5-conc-17-s31"><label>||</label>University Health Network and The University of Toronto</aff><author-notes><corresp id="c1-conc-17-s31">Correspondence to: Suzanne Kamel-Reid, University Health Network, Dept. of Pathology, 11 Eaton North, Rm. 213 - 200 Elizabeth St. Toronto, Ontario, Canada <bold><italic>E-mail</italic></bold>: <email>suzanne.kamel-reid@uhn.on.ca</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2010</year></pub-date><volume>17</volume><issue>Suppl 1</issue><fpage>S31</fpage><lpage>S40</lpage><permissions><copyright-statement>2010 Multimed Inc.</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Survival of patients with metastatic CRC (mCRC) has improved steadily over the past several decades, due largely to the development of new combinations of standard chemotherapy, as well as to the introduction of new targeted therapies. Among the available targeted therapies are two monoclonal antibodies that target the epidermal growth factor receptor (EGFR) &#x02013; cetuximab and panitumumab &#x02013; which have demonstrated efficacy in the treatment of mCRC. These therapies are associated with a unique set of toxicities and costs, prompting the need for tools to select patients who are most likely to derive a benefit from them. Mutations in the <italic>KRAS</italic> oncogene have consistently been shown to predict non-response to cetuximab and panitumumab. The role of KRAS as a marker of efficacy of anti-EGFR therapies is reviewed.</p></abstract><kwd-group><kwd>KRAS</kwd><kwd>EGFR</kwd><kwd>colorectal carcinoma</kwd><kwd>cetuximab</kwd><kwd>panitumumab</kwd><kwd>genetic testing methods</kwd></kwd-group></article-meta></front><body><sec><label>1.</label><title>INTRODUCTION</title><p>Colorectal cancer (CRC) affects more than 21,000 Canadians each year, and is the second leading cause of death from cancer among Canadian men and women<xref ref-type="bibr" rid="b1-conc-17-s31">1</xref>. Survival of patients with metastatic CRC (mCRC) has improved steadily over the past several decades, due largely to the development of new combinations of standard chemotherapy such as 5-fluorouracil, irinotecan, and oxaliplatin, as well as to the introduction of new targeted therapies. Among the available targeted therapies are two monoclonal antibodies that target the epidermal growth factor receptor (EGFR) &#x02013; cetuximab and panitumumab &#x02013; which have clearly demonstrated efficacy in the treatment of mCRC. However, the introduction of these therapies has also introduced a unique set of toxicities and increased costs<xref ref-type="bibr" rid="b2-conc-17-s31">2</xref>, prompting the need for tools to select the patients who are most likely to benefit from these therapies.</p><p>There has recently been heightened interest in the relevance of several biomarkers for the selection of patients who will benefit from EGFR-targeted therapies for the treatment of CRC and other EGFR-associated cancers. In particular, mutations in the <italic>KRAS</italic> oncogene have consistently been shown to predict nonresponse to cetuximab and panitumumab. This marker is of particular importance, given the prevalence of <italic>KRAS</italic> mutations among patients with CRC; up to half of patients with CRC are found to have the mutant version of the gene<xref ref-type="bibr" rid="b3-conc-17-s31">3</xref>&#x02013;<xref ref-type="bibr" rid="b6-conc-17-s31">6</xref>.</p><sec><label>1.1</label><title><italic>KRAS</italic> and the EGFR pathway</title><p><italic>KRAS</italic> is a signal transducer downstream of tyrosine kinase receptors including EGFR &#x02013; a complex signaling cascade involved in the development and progression of cancer. The EGFR pathway is activated by the binding of the cell-surface EGFR/HER family receptors to their ligands, such as transforming growth factor alpha (TGF- &#x003b1;) and EGF. This leads to activation of genes that regulate cell cycle progression, tumor cell survival, metastases and angiogenesis (<xref ref-type="fig" rid="f1-conc-17-s31">Fig. 1</xref>). Monoclonal antibodies against EGFR, such as cetuximab and panitumumab, block the receptor signaling and its downstream events, including those mediated by <italic>KRAS</italic>.</p><p>Upon stimulation of the EGFR, wild-type <italic>KRAS</italic> is active for a short period and the signaling activities to the downstream RAF/mitogen-activated protein kinase (MAPK)/extracellular signal-related kinase (ERK) pathway are tightly controlled. Mutated <italic>KRAS</italic> protein becomes constitutively activated, thereby making the cascade independent of upstream signaling by tyrosine kinase receptors such as the EGFR. Therefore, blocking of EGFR with cetuximab or panitumumab may not affect downstream events. Mutations within the <italic>KRAS</italic> gene resulting in constitutive protein activity are found in approximately 30% to 50% of all CRCs<xref ref-type="bibr" rid="b3-conc-17-s31">3</xref>&#x02013;<xref ref-type="bibr" rid="b6-conc-17-s31">6</xref>.</p></sec><sec><label>1.2</label><title>The role of <italic>KRAS</italic> and BRAF as markers of efficacy of the anti-EGFR therapy</title><sec><label>1.2.1</label><title>KRAS</title><p>As reviewed by Fakih and Wong in this supplement, the efficacy of the anti-EGFR antibodies cetuximab and panitumumab in the treatment of mCRC has consistently been shown to rely on the <italic>KRAS</italic> status of the tumor (<xref ref-type="table" rid="t1-conc-17-s31">Tables 1</xref> and <xref ref-type="table" rid="t2-conc-17-s31">2</xref>). Post hoc analyses of both randomized and single-arm trials of cetuximab or panitumumab have demonstrated that these monoclonal antibodies are only effective against tumors with wild-type <italic>KRAS</italic>, while patients with <italic>KRAS</italic> mutations in codon 12 or 13 do not derive any benefit from these treatments<xref ref-type="bibr" rid="b3-conc-17-s31">3</xref>,<xref ref-type="bibr" rid="b4-conc-17-s31">4</xref>,<xref ref-type="bibr" rid="b6-conc-17-s31">6</xref>&#x02013;<xref ref-type="bibr" rid="b11-conc-17-s31">11</xref>.</p><p>The first study to provide conclusive data showing the relationship between <italic>KRAS</italic> status and the efficacy of the monoclonal anti-EGFR antibody panitumumab was Amado&#x02019;s analysis of tumors from 427 mCRC patients who were randomly assigned to treatment with panitumumab or best supportive care (BSC)<xref ref-type="bibr" rid="b6-conc-17-s31">6</xref>. Treatment response and improvement in progression-free survival (PFS) with panitumumab monotherapy were both limited to patients with wild-type <italic>KRAS</italic>. Of the 84 panitumumab treated patients with <italic>KRAS</italic> mutations, none responded to the treatment. In contrast, 21 of 124 antibody-treated patients with wild-type <italic>KRAS</italic> tumors experienced a partial response. Among patients with wild-type <italic>KRAS</italic>, PFS was significantly improved with panitumumab compared with BSC alone (HR 0.45; 95% CI 0.34&#x02013;0.59; median PFS 12.3 weeks for panitumumab vs. 7.3 weeks for BSC), while no benefit was observed among those with mutant <italic>KRAS</italic> (HR 0.99; 95% CI 0.73&#x02013;1.36; median PFS of 7.4 weeks for panitumumab vs. 7.3 weeks for BSC).</p><p>Similar results have been demonstrated with cetuximab. In a retrospective analysis of 540 mutation assessable patients in the CRYSTAL (Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer) trial, <italic>KRAS</italic> mutations were identified in 35.6%<xref ref-type="bibr" rid="b4-conc-17-s31">4</xref>. For patients with wild-type <italic>KRAS</italic>, the addition of cetuximab to folinic acid, fluorouracil, and irinotecan (FOLFIRI) improved both PFS (9.9 vs. 8.7 months; HR 0.68; P=0.017) and response rate (59.3% vs. 43.2%; P=0.0025). In contrast, for patients with <italic>KRAS</italic> mutations, treatment with cetuximab did not significantly improve either PFS (7.6 vs. 8.1 months; HR 1.07; P=0.47) or response rate (40.2% vs. 36.2%; P=0.46) in comparison with FOLFIRI alone. In the OPUS (Oxaliplatin and Cetuximab for First-Line Treatment of Metastatic Colorectal Cancer) study, patients were treated with first-line infused fluorouracil, folinic acid, and oxaliplatin (FOLFOX) with or without cetuximab<xref ref-type="bibr" rid="b3-conc-17-s31">3</xref>. Response rate and PFS were both significantly improved in patients treated with cetuximab; however, these benefits were limited to those with wild-type <italic>KRAS</italic> tumors, and patients with mutated <italic>KRAS</italic> receiving cetuximab demonstrated poorer outcomes than those receiving FOLFOX alone.</p><p>The phase III CO.17 trial, conducted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) in collaboration with the Australasian Gastro-Intestinal Trials Group (AGITG), examined the effect of cetuximab on survival among patients with advanced CRC in whom all chemotherapy had failed and for whom no other standard anticancer therapy was available<xref ref-type="bibr" rid="b12-conc-17-s31">12</xref>. Although cetuximab used alone in the third-line setting improved overall survival and PFS and preserved quality of life to a better degree than BSC alone, resistance to cetuximab was high, with more than half of the cetuximab-treated patients showing progression at the first assessment of disease response. With the accumulating evidence demonstrating the ineffectiveness of anti-EGFR in patients with <italic>KRAS</italic> mutations, the study group undertook correlative analyses to determine whether the mutation status of the <italic>KRAS</italic> gene modified the effect of cetuximab on the overall survival (OS) and PFS in the CO.17 patient population<xref ref-type="bibr" rid="b9-conc-17-s31">9</xref>. A total of 394 tumor samples &#x02013; 198 from the cetuximab group and 196 from the BSC group &#x02013; were available for <italic>KRAS</italic> analysis, accounting for 68.9% of the original study population. <italic>KRAS</italic> mutations were detected in 40.9% and 42.3% of tumors from the cetuximab and BSC groups, respectively. Among patients with wild-type <italic>KRAS</italic>, median overall survival was significantly longer in the cetuximab group (9.5 months) than in the BSC group (4.8 months), with one-year overall survival rates of 28.3% and 20.1%, respectively (HR 0.55, 95% CI 0.41&#x02013;0.74, P&#x0003c;0.001). However, among patients with <italic>KRAS</italic> mutations, overall survival was not improved with cetuximab, with a median survival of 4.5 months vs. 4.6 months with BSC alone, and one-year overall survival rates of 13.2% and 19.6%, respectively (HR 0.98, 95% CI 0.70&#x02013;1.37, p=0.89). These results were instrumental in defining the indication for the monoclonal antibody EGFR inhibitors in North America.</p></sec><sec><label>1.2.2</label><title>BRAF</title><p>In the absence of <italic>KRAS</italic> mutations, resistance to anti-EGFR therapies may occur as a result of mutations in other signaling molecules in the RAS-RAF-MAPK pathway. Recent retrospective analyses of mCRC patients treated with cetuximab or panitumumab have shown that BRAF mutations, which are exclusive from <italic>KRAS</italic> mutations, occur in approximately14% of patients and are also associated with a lack of response to anti-EGFR therapy<xref ref-type="bibr" rid="b13-conc-17-s31">13</xref>,<xref ref-type="bibr" rid="b14-conc-17-s31">14</xref>. BRAF mutations have also been associated with significantly shorter PFS<xref ref-type="bibr" rid="b13-conc-17-s31">13</xref>,<xref ref-type="bibr" rid="b14-conc-17-s31">14</xref> and overall survival<xref ref-type="bibr" rid="b13-conc-17-s31">13</xref> in patients with mCRC.</p></sec></sec></sec><sec><label>2.</label><title>METHODS FOR KRAS TESTING</title><sec><label>2.1</label><title>Guidelines for testing</title><p>In Canada, panitumumab is currently restricted to the treatment of EGFR-expressing mCRC with non-mutated (wild-type) <italic>KRAS</italic><xref ref-type="bibr" rid="b15-conc-17-s31">15</xref>, while KRAS status is not specified in the indication for cetuximab<xref ref-type="bibr" rid="b16-conc-17-s31">16</xref>. However, with the knowledge that patients with mCRC who harbour <italic>KRAS</italic> mutations do not derive any benefit from treatment with EGFR-targeting monoclonal antibodies in the first-, second-, or third-line settings, Cancer Care Ontario (CCO) recommends the two clinically available EGFR inhibitors, cetuximab and panitumumab, be used &#x0201c;for the treatment of patients with advanced CRC after failure of standard chemotherapy and whose tumors have tested negative for <italic>KRAS</italic> gene mutations&#x0201d;<xref ref-type="bibr" rid="b17-conc-17-s31">17</xref>. CCO has also recently approved the use of cetuximab in combination with irinotecan for the third-line treatment of mCRC only in the presence of tumors with the non-mutated KRAS oncogene.</p><p>The American Society of Clinical Oncology (ASCO) recently also released a provisional clinical opinion recommending that patients with mCRC who are candidates for treatment with cetuximab or panitumumab undergo tumor testing for <italic>KRAS</italic> mutations in a CLIA-accredited laboratory<xref ref-type="bibr" rid="b18-conc-17-s31">18</xref>. The updated National Comprehensive Cancer Network (NCCN) clinical practice guidelines for colon cancer and rectal cancer also recommend testing for <italic>KRAS</italic> gene mutations, stipulating that only patients with wild-type <italic>KRAS</italic> genes should receive treatment with cetuximab or panitumumab<xref ref-type="bibr" rid="b19-conc-17-s31">19</xref>,<xref ref-type="bibr" rid="b20-conc-17-s31">20</xref>.</p><p>However, BRAF testing is currently not a requirement for treatment with an EGFR inhibitor.</p></sec><sec><label>2.2</label><title>How to test?</title><p>By screening patients with mCRC for <italic>KRAS</italic> tumor status prior to initiating treatment with an anti-EGFR monoclonal antibody, unnecessary toxicity and costs can be avoided for patients who are unlikely to respond. However, there are logistical challenges in testing tumors from mCRC patients, as well as questions surrounding specimen selection, and selection of the appropriate assay.</p></sec><sec><label>2.3</label><title>Specimen selection</title><p>The most readily available clinical specimens for mutational analysis are typically formalin-fixed, paraffin-embedded (FFPE) tissue blocks. Until recently, formalin-fixed samples were considered to be of low quality and yield for DNA testing<xref ref-type="bibr" rid="b21-conc-17-s31">21</xref>; however, improvements in techniques have enhanced the ability to use DNA from FFPE tissue<xref ref-type="bibr" rid="b22-conc-17-s31">22</xref>. Because the fixation process damages DNA and can potentially introduce artificial mutations in conventional PCR processes, sufficient cellular material is necessary for analysis<xref ref-type="bibr" rid="b23-conc-17-s31">23</xref>. DNA from surrounding reactive cells, such as fibroblasts, leukocytes, or endothelial cells, can also potentially compete with mutant DNA in amplification reactions and introduce errors in testing. Tumor cell enrichment by micro- or macro-dissection or selective sampling of the paraffin block by needle core may increase the sensitivity of mutation testing, but care must be taken with these procedures to ensure that sufficient DNA is available for amplification<xref ref-type="bibr" rid="b22-conc-17-s31">22</xref> and contamination of normal DNA with mutant DNA does not occur.</p><p>Based on current knowledge, the most appropriate specimens for <italic>KRAS</italic> mutation testing may be obtained from the primary tumor<xref ref-type="bibr" rid="b24-conc-17-s31">24</xref>. However, an estimated 20% of patients will present with metastatic disease and, therefore, lack tissues from the primary tumor<xref ref-type="bibr" rid="b24-conc-17-s31">24</xref>. In these patients, <italic>KRAS</italic> testing may be performed using material from the metastatic tumor<xref ref-type="bibr" rid="b24-conc-17-s31">24</xref>. Data comparing <italic>KRAS</italic> status in primary and metastatic tumors are limited and have had inconsistent results<xref ref-type="bibr" rid="b25-conc-17-s31">25</xref>&#x02013;<xref ref-type="bibr" rid="b28-conc-17-s31">28</xref>. However, in a recent Italian study of 48 patients with mCRC, DNA sequencing revealed an overall concordance of <italic>KRAS</italic> mutational status between primary tumors and metastases in 92% of patients, suggesting that evaluation of <italic>KRAS</italic> status can be performed in either the primary tumor or metastatic sites<xref ref-type="bibr" rid="b29-conc-17-s31">29</xref>.</p></sec><sec><label>2.4</label><title>Assay selection</title><p>Several mutation detection procedures have been described, all of which are based on the polymerase chain reaction (PCR) (<xref ref-type="table" rid="t3-conc-17-s31">Table 3</xref>)<xref ref-type="bibr" rid="b22-conc-17-s31">22</xref>. Generally, selection of the best technique for use is based on the sample size, desired level of sensitivity and DNA quality and quantity available.</p></sec><sec><label>2.5</label><title>Direct sequencing of PCR products</title><p>Direct sequencing of PCR products detects all mutations in amplified DNA sequences, and this is currently the most commonly used method for <italic>KRAS</italic> testing<xref ref-type="bibr" rid="b30-conc-17-s31">30</xref>. However, this method requires mutant copies to have a minimum concentration of 20% to 50% that of any accompanying wild-type sequences, and will therefore miss mutations that may be present at a lower level <xref ref-type="bibr" rid="b21-conc-17-s31">21</xref>,<xref ref-type="bibr" rid="b31-conc-17-s31">31</xref>. Because of the low sensitivity and the expense of direct sequencing, more sensitive and specific assays have been developed to assess <italic>KRAS</italic> in clinical samples, including methods that employ restriction fragmentation length polymorphism (RFLP), allele-specific oligonucleotide (ASO) hybridization, high resolution melting analysis (HRMA), and amplification refractory mutation systems (ARMS).</p></sec><sec><label>2.6</label><title>RFLP</title><p>Whereas gene sequencing compares the sequence of the sample gene with the normal sequence of the gene, nucleotide by nucleotide, RFLP methods detect differences between mutant and wild-type DNA by their susceptibility to digestion by restriction enzymes. Restriction enzymes can be selected to recognize a defined sequence which is present only in the mutated or non-mutated DNA. Knowing what specific size the digested fragment should be in mutated vs. non-mutated DNA allows one to identify if a mutation is present or not. These amplified mutant copies can then be detected by gel or capillary electrophoresis<xref ref-type="bibr" rid="b32-conc-17-s31">32</xref>. While highly sensitive, this method is also very complex, requiring tight control of PCR and digestion conditions to avoid replication errors and artificial mutations. Furthermore, when a mutation is detected by this methodology the specific nucleotide change cannot be identified. If the specific mutation identity is required (this is not currently necessary for clinical utility), then direct sequencing can be used after mutation identification by RFLP.</p></sec><sec><label>2.7</label><title>Allele-specific oligonucleotide hybridization</title><p>Short segments of synthetically produced DNA (oligonucleotides) can be used to detect mutations in a gene segment. The oligonucleotides are complementary to a corresponding segment of the gene under investigation, hybridizing completely with the wild-type sequence or to one of the possible mutations. A single base mismatch caused by a mutation reduces the melting point temperature of the double-stranded hybrid<xref ref-type="bibr" rid="b33-conc-17-s31">33</xref>. The difference in melting points between matched and mismatched sequences can be used to detect single-base mismatches between wild-type and mutant sequences<xref ref-type="bibr" rid="b34-conc-17-s31">34</xref>.</p><p>Finding rare mutant alleles in a DNA mixture can be challenging however, particularly in samples containing high levels of normal alleles. Therefore, if a sample has a low tumor burden, this may not be the best approach. This technique is also expensive, requiring specialized equipment and software for analysis<xref ref-type="bibr" rid="b35-conc-17-s31">35</xref>.</p></sec><sec sec-type="methods"><label>2.8</label><title>High resolution melting analysis</title><p>The presence of a mutation disrupts the affinity of two DNA chains, causing them to bind with less energy and become more easily separated by heat. High resolution melting analysis (HRMA) is performed following PCR, and measures differences in melting point temperatures between matched and mismatched double stranded DNA, caused by polymorphisms or somatic mutations<xref ref-type="bibr" rid="b35-conc-17-s31">35</xref>. HRMA has a high sensitivity, and is also inexpensive and fast. However, because any DNA alteration can produce an abnormal melting point curve, abnormal curves need to be confirmed by sequencing, which increases turnaround time and expense, reducing HRMA&#x02019;s advantage over direct sequencing alone. HRMA may therefore be useful for rapid screening; however the need for confirmation by sequencing may limit its utility in the clinical setting.</p></sec><sec><label>2.9</label><title>Amplification refractory mutation system</title><p>The amplification refractory mutation system (ARMS) &#x02013; also known as allele-specific PCR or PCR amplification of specific alleles &#x02013; utilizes a PCR primer which is designed to discriminate among templates that differ by a single nucleotide residue. The ARMS primer can be designed to amplify a specific allele of a multi-allelic system while remaining refractory to amplification of another allele that may differ by as little as a single base. ARMS is able to detect directly the presence of <italic>KRAS</italic> mutations in heterogeneous specimens at a low allelic concentration (1%) without the need for confirmation by direct sequencing. A drawback of ARMS is that it is only able to detect known mutations; separate reactions are required for each mutation, thus requiring more DNA material. However, because the amplification step and the diagnostic steps are combined, this may prove to be a time-efficient and practical method for routine diagnosis of <italic>KRAS</italic> mutations<xref ref-type="bibr" rid="b22-conc-17-s31">22</xref>.</p></sec><sec><label>2.10</label><title>Standardization of <italic>KRAS</italic> testing in colorectal cancer</title><p>Because of the potential for variability among the different testing methods, a thorough analytical validation of testing methods, together with a high standard of quality assurance are critical for accurate, reliable testing of <italic>KRAS</italic> mutations in clinical practice<xref ref-type="bibr" rid="b24-conc-17-s31">24</xref>. In Canada, Health Canada has approved the use of the TheraScreen K-RAS testing kit (DxS, Manchester, United Kingdom), which combines ARMS with a real time PCR technology. In the United States, there is currently no FDA-approved test for <italic>KRAS</italic> testing, and testing can be performed using laboratory-developed tests, provided that the laboratory is accredited by the College of American Pathologists (CAP) and the test has been appropriately validated.<xref ref-type="bibr" rid="b36-conc-17-s31">36</xref> To date, one published study has evaluated the concordance between different methods for <italic>KRAS</italic> mutation testing<xref ref-type="bibr" rid="b37-conc-17-s31">37</xref>. Four commercially available assays were used to assess seven common mutations of the <italic>KRAS</italic> gene in codons 12 and 13 in 40 colorectal tumor samples, with direct sequencing used as a reference. Two of the allele-specific PCR-based methods and one PCR/direct sequencing method demonstrated high to good agreement with direct sequencing, whereas an oligonucleotide hybridization method showed poor agreement.</p></sec></sec><sec sec-type="results"><label>3.</label><title>RESULTS</title><p>The authors of the present article conducted a small study involving six Canadian laboratories to compare the accuracy and sensitivity of three methods of <italic>KRAS</italic> mutation analysis &#x02013; the TheraScreen K-RAS testing kit only (1 laboratory), the TheraScreen K-RAS testing kit in combination with direct sequencing (2 laboratories), the TheraScreen K-RAS testing kit in combination with direct sequencing and RFLP (1 laboratory), and RFLP plus sequencing (2 laboratories). In the first phase of the study, 10 DNA samples were extracted from seven <italic>KRAS</italic> mutant (positive) cell lines containing approximately 50&#x02013;100% mutant cells. In the second phase, dilutions were created from each of the seven positive cell lines (approximately 10&#x02013;40% mutant cells). To assess the ability of the laboratory to extract DNA from paraffin and the resulting specificity, accuracy and sensitivity of <italic>KRAS</italic> mutation testing on such samples, 8&#x02013;10 samples were extracted from paraffin blocks for the third phase of the study. For each phase, <italic>KRAS</italic>-negative cell lines were used for comparison.</p><p>All of the labs were able to detect <italic>KRAS</italic> mutations in samples derived from cell lines containing 50&#x02013;100% mutant <italic>KRAS</italic> cells as well as from diluted cells lines containing 10&#x02013;40% mutant <italic>KRAS</italic> cells. However, two of the labs experienced some difficulty interpreting two samples from the diluted cell lines when using sequencing methodology; this is probably due to the limits of sensitivity of sequencing.</p><p>Concordant results were achieved with five of the eight samples extracted from paraffin blocks. Inconsistent results with RFLP plus sequencing were seen in one lab, which was later discovered to be due to a mix-up of the samples (Lab 5, samples 3 and 4, <xref ref-type="table" rid="t4-conc-17-s31">Table 4</xref>). Discordant results were reported for three of the eight samples. In sample four, results were not concordant as the sample had a low level <italic>KRAS</italic> mutation requiring a very sensitive assay, prompting the question of what the sensitivity cutoff of an assay should be. In sample six, two labs reported inconclusive results using the TheraScreen test, suggesting that labs reporting inconclusive results with this test should reconsider their delta-Ct cutoff criteria, optimize their assay, or use another method to verify the results. In sample eight, most of the labs had some difficulty in interpreting the mutation status due to the limited tumor area on the slides and a non-formalin based fixation method, resulting in low DNA yield and poor DNA quality. The labs that participated are all well-experienced in performing complex genetic analyses on various sample types. These results thus point to some of the challenges of <italic>KRAS</italic> testing in poor quality samples.</p></sec><sec sec-type="conclusions"><label>4.</label><title>CONCLUSIONS</title><p>In all clinical trials, anti-EGFR therapies have been consistently ineffective in mCRC patients with <italic>KRAS</italic> mutations. Targeting these therapies based on <italic>KRAS</italic> status will not only spare patients ineffective and toxic therapies, but will also greatly reduce unnecessary costs. The economic implications of customizing anti-EGFR therapy based on <italic>KRAS</italic> status was recently evaluated by Shakaran et al., using estimated incidence rates for new mCRC cases in the United States<xref ref-type="bibr" rid="b38-conc-17-s31">38</xref>. Based on an annual incidence of 29,762 new cases of mCRC cases, the cost of upfront <italic>KRAS</italic> testing was calculated at $13 million ($452/patient). By treating only the estimated 64.4% of patients with wild-type <italic>KRAS</italic>, net savings were estimated to be $740 million in the U.S. Although cetuximab is used more commonly in the third-line setting where treatment duration is shorter, targeting treatment based on <italic>KRAS</italic> status is likely to result in cost savings across all lines of therapy<xref ref-type="bibr" rid="b38-conc-17-s31">38</xref>.</p><p>Testing techniques need to be standardized and validated externally as well as internally. Cell line materials provided the most accurate results, while paraffin-embedded tissue may be somewhat more problematic, especially if suboptimal.</p><p>The role of the pathologist is very important in <italic>KRAS</italic> testing. The pathologist is responsible for choosing the most appropriate tissue block to be tested, evaluating the tumor content of the tissue block, and ensuring that it is adequate (tissue size, degree of tumor involvement) by assessing the H&#x00026;E-stained section of the tissue area and marking the area with adequate tumor density &#x02013; preferably &#x0003e;70% carcinoma cells. Testing should be performed by an accredited and licensed testing lab that conforms to quality guidelines for <italic>KRAS</italic> testing<xref ref-type="bibr" rid="b24-conc-17-s31">24</xref> and routinely participates in proficiency testing (e.g. the College of American Pathologists [CAP]).</p><p>We propose an algorithmic approach to <italic>KRAS</italic> testing, where laboratory professionals (pathologists, geneticists) have access to multiple methods wherever possible, especially when assessing suboptimal material. We have found that for small samples with degraded DNA, Sanger sequencing is often still the best method for mutation detection.</p><p>Regardless of the testing method used to determine <italic>KRAS</italic> status in patients with mCRC, the goal is for a sensitive and specific technique that has been standardized and validated externally and internally. As noted above, CAP currently has a proficiency challenge available for labs so they can assess their ability to test for <italic>KRAS</italic> mutations.</p><p>The anti-EGFR monoclonal antibody therapies are currently approved for the treatment of mCRC in the third-line setting. However, it may be several weeks before results of <italic>KRAS</italic> testing are obtained, which can be a long wait for a patient with advanced disease who requires treatment. Depending on the availability of funding, it would be optimal for KRAS testing to begin immediately following a diagnosis of metastatic disease; currently however, testing can only be undertaken when the Oncologist is considering third-line therapy.</p></sec></body><back><ack><title>5. ACKNOWLEDGEMENTS</title><p>The authors acknowledge the support of Bristol-Myers Squibb Inc. in providing funding for third-party medical writing. The authors also acknowledge the medical writing contributions of Maryka Hladki of Science &#x00026; Medicine Canada.</p></ack><ref-list><title>6. REFERENCES</title><ref id="b1-conc-17-s31"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Canadian Cancer Society&#x02019;s Steering Committee</collab></person-group><source>Canadian Cancer Statistics 2009</source><publisher-loc>Toronto, ON</publisher-loc><publisher-name>Canadian Cancer Society</publisher-name><year>2009</year></element-citation></ref><ref id="b2-conc-17-s31"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrag</surname><given-names>D</given-names></name></person-group><article-title>The price tag on progress: chemotherapy for colorectal cancer</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>317</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15269308</pub-id></element-citation></ref><ref id="b3-conc-17-s31"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>Bondarenko</surname><given-names>I</given-names></name><name><surname>Hartmann</surname><given-names>JT</given-names></name><etal/></person-group><article-title>KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>May 20 suppl</issue><fpage>4000</fpage></element-citation></ref><ref id="b4-conc-17-s31"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Lang</surname><given-names>I</given-names></name><name><surname>D&#x02019;haens</surname><given-names>G</given-names></name><etal/></person-group><article-title>KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>May 5 suppl</issue><fpage>2</fpage></element-citation></ref><ref id="b5-conc-17-s31"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khambata-Ford</surname><given-names>S</given-names></name><name><surname>Garrett</surname><given-names>CR</given-names></name><name><surname>Meropol</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>3230</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">17664471</pub-id></element-citation></ref><ref id="b6-conc-17-s31"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amado</surname><given-names>RG</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name><name><surname>Peeters</surname><given-names>M</given-names></name><etal/></person-group><article-title>Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>1626</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">18316791</pub-id></element-citation></ref><ref id="b7-conc-17-s31"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Fiore</surname><given-names>F</given-names></name><name><surname>Blanchard</surname><given-names>F</given-names></name><name><surname>Charbonnier</surname><given-names>F</given-names></name><etal/></person-group><article-title>Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy</article-title><source>Br J Cancer</source><year>2007</year><volume>96</volume><fpage>1166</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">17375050</pub-id></element-citation></ref><ref id="b8-conc-17-s31"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Roock</surname><given-names>W</given-names></name><name><surname>Piessevaux</surname><given-names>H</given-names></name><name><surname>De Schutter</surname><given-names>J</given-names></name><etal/></person-group><article-title>KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab</article-title><source>Ann Oncol</source><year>2008</year><volume>19</volume><fpage>508</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">17998284</pub-id></element-citation></ref><ref id="b9-conc-17-s31"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karapetis</surname><given-names>CS</given-names></name><name><surname>Khambata-Ford</surname><given-names>S</given-names></name><name><surname>Jonker</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>K-ras mutations and benefit from cetuximab in advanced colorectal cancer</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>1757</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">18946061</pub-id></element-citation></ref><ref id="b10-conc-17-s31"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li&#x000e8;vre</surname><given-names>A</given-names></name><name><surname>Bachet</surname><given-names>JB</given-names></name><name><surname>Boige</surname><given-names>V</given-names></name><etal/></person-group><article-title>KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>374</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">18202412</pub-id></element-citation></ref><ref id="b11-conc-17-s31"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punt</surname><given-names>CJ</given-names></name><name><surname>Tol</surname><given-names>J</given-names></name><name><surname>Rodenburg</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>180 suppl</issue><fpage>LBA4011</fpage></element-citation></ref><ref id="b12-conc-17-s31"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonker</surname><given-names>DJ</given-names></name><name><surname>O&#x02019;Callaghan</surname><given-names>CJ</given-names></name><name><surname>Karapetis</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Cetuximab for the treatment of colorectal cancer</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>2040</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">18003960</pub-id></element-citation></ref><ref id="b13-conc-17-s31"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Nicolantonio</surname><given-names>F</given-names></name><name><surname>Martini</surname><given-names>M</given-names></name><name><surname>Molinari</surname><given-names>F</given-names></name><etal/></person-group><article-title>Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>5705</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">19001320</pub-id></element-citation></ref><ref id="b14-conc-17-s31"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruzzo</surname><given-names>A</given-names></name><name><surname>Cremolini</surname><given-names>C</given-names></name><name><surname>Loupakis</surname><given-names>F</given-names></name><etal/></person-group><article-title>Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>15 suppl</issue><fpage>4058</fpage></element-citation></ref><ref id="b15-conc-17-s31"><label>15.</label><element-citation publication-type="book"><source>Vectibix&#x02122; (panitumumab) Product Monograph</source><publisher-loc>Mississauga, Ontario</publisher-loc><publisher-name>Amgen</publisher-name><month>3</month><year>2009</year></element-citation></ref><ref id="b16-conc-17-s31"><label>16.</label><element-citation publication-type="book"><source>Erbitux (cetuximab) Product Monograph</source><publisher-loc>Montreal, Quebec</publisher-loc><publisher-name>Bristol-Myers Squibb Canada</publisher-name><month>3</month><year>2009</year></element-citation></ref><ref id="b17-conc-17-s31"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jonker</surname><given-names>D</given-names></name><name><surname>Biagi</surname><given-names>J</given-names></name><name><surname>Haynes</surname><given-names>AE</given-names></name></person-group><article-title>The use of epidermal growth factor receptor inhibitors in advanced colorectal cancer</article-title><source>Committee to Evaluate Drugs/CCO Special Advice Report #8</source><publisher-loc>Toronto, ON</publisher-loc><publisher-name>Cancer Care Ontario</publisher-name><year>2008</year></element-citation></ref><ref id="b18-conc-17-s31"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allegra</surname><given-names>CJ</given-names></name><name><surname>Jessup</surname><given-names>JM</given-names></name><name><surname>Somerfield</surname><given-names>MR</given-names></name><etal/></person-group><article-title>American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>2091</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">19188670</pub-id></element-citation></ref><ref id="b19-conc-17-s31"><label>19.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>National Comprehensive Cancer Network</collab></person-group><article-title>NCCN Clinical Practice Guidelines in Oncology: Colon Cancer</article-title>V.2.2009. Accessed at <ext-link ext-link-type="uri" xlink:href="www.nccn.org/professionals/physician_gls/PDF/colon.pdf">www.nccn.org/professionals/physician_gls/PDF/colon.pdf</ext-link> on November 30, 2009.</mixed-citation></ref><ref id="b20-conc-17-s31"><label>20.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>National Comprehensive Cancer Network</collab></person-group><article-title>NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer</article-title>V.2.2009. Accessed at <ext-link ext-link-type="uri" xlink:href="www.nccn.org/professionals/physician_gls/PDF/rectal.pdf">www.nccn.org/professionals/physician_gls/PDF/rectal.pdf</ext-link> on November 30, 2009.</mixed-citation></ref><ref id="b21-conc-17-s31"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frayling</surname><given-names>IM</given-names></name></person-group><article-title>Methods of molecular analysis: mutation detection in solid tumours</article-title><source>Mol Pathol</source><year>2002</year><volume>55</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">11950952</pub-id></element-citation></ref><ref id="b22-conc-17-s31"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimeno</surname><given-names>A</given-names></name><name><surname>Messersmith</surname><given-names>WA</given-names></name><name><surname>Hirsch</surname><given-names>FR</given-names></name><etal/></person-group><article-title>KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>1130</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">19124802</pub-id></element-citation></ref><ref id="b23-conc-17-s31"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>Pont&#x000e9;n</surname><given-names>F</given-names></name><name><surname>Moberg</surname><given-names>C</given-names></name><etal/></person-group><article-title>A high frequency of sequence alterations is due to formalin fixation of archival specimens</article-title><source>Am J Pathol</source><year>1999</year><volume>155</volume><fpage>1467</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">10550302</pub-id></element-citation></ref><ref id="b24-conc-17-s31"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Krieken</surname><given-names>JH</given-names></name><name><surname>Jung</surname><given-names>A</given-names></name><name><surname>Kirchner</surname><given-names>T</given-names></name><etal/></person-group><article-title>KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program</article-title><source>Virchows Arch</source><year>2008</year><volume>453</volume><fpage>417431</fpage></element-citation></ref><ref id="b25-conc-17-s31"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oudejans</surname><given-names>JJ</given-names></name><name><surname>Slebos</surname><given-names>RJ</given-names></name><name><surname>Zoetmulder</surname><given-names>FA</given-names></name><etal/></person-group><article-title>Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver</article-title><source>Int J Cancer</source><year>1991</year><volume>49</volume><fpage>875</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">1959991</pub-id></element-citation></ref><ref id="b26-conc-17-s31"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suchy</surname><given-names>B</given-names></name><name><surname>Zietz</surname><given-names>C</given-names></name><name><surname>Rabes</surname><given-names>HM</given-names></name></person-group><article-title>K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis</article-title><source>Int J Cancer</source><year>1992</year><volume>52</volume><fpage>30</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">1500224</pub-id></element-citation></ref><ref id="b27-conc-17-s31"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Mulla</surname><given-names>F</given-names></name><name><surname>Going</surname><given-names>JJ</given-names></name><name><surname>Sowden</surname><given-names>ET</given-names></name><etal/></person-group><article-title>Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality</article-title><source>J Pathol</source><year>1998</year><volume>185</volume><fpage>130</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">9713338</pub-id></element-citation></ref><ref id="b28-conc-17-s31"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tortola</surname><given-names>S</given-names></name><name><surname>Steinert</surname><given-names>R</given-names></name><name><surname>Hantschick</surname><given-names>M</given-names></name><etal/></person-group><article-title>Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer</article-title><source>J Clin Oncol</source><year>2001</year><volume>19</volume><fpage>2837</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">11387355</pub-id></element-citation></ref><ref id="b29-conc-17-s31"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artale</surname><given-names>S</given-names></name><name><surname>Sartore-Bianchi</surname><given-names>A</given-names></name><name><surname>Veronese</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>4217</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">18757341</pub-id></element-citation></ref><ref id="b30-conc-17-s31"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nollau</surname><given-names>P</given-names></name><name><surname>Wagener</surname><given-names>C</given-names></name></person-group><article-title>Methods for detection of point mutations: performance and quality assessment. IFCC Scientific Division, Committee on Molecular Biology Techniques</article-title><source>Clin Chem</source><year>1997</year><volume>43</volume><fpage>1114</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">9216447</pub-id></element-citation></ref><ref id="b31-conc-17-s31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallegos Ruiz</surname><given-names>MI</given-names></name><name><surname>Floor</surname><given-names>K</given-names></name><name><surname>Rijmen</surname><given-names>F</given-names></name><etal/></person-group><article-title>EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens</article-title><source>Cell Oncol</source><year>2007</year><volume>29</volume><fpage>257</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">17452778</pub-id></element-citation></ref><ref id="b32-conc-17-s31"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>S</given-names></name><name><surname>Urbano-Ispizua</surname><given-names>A</given-names></name><name><surname>Gill</surname><given-names>R</given-names></name><etal/></person-group><article-title>Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique</article-title><source>Cancer Res</source><year>1991</year><volume>51</volume><fpage>3497</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">1675933</pub-id></element-citation></ref><ref id="b33-conc-17-s31"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>RB</given-names></name><name><surname>Johnson</surname><given-names>MJ</given-names></name><name><surname>Hirose</surname><given-names>T</given-names></name><etal/></person-group><article-title>The use of synthetic oligonucleotides as hybridization probes: II. Hybridization of oligonucleotides of mixed sequence to rabbit beta-globin DNA</article-title><source>Nucleic Acids Res</source><year>1981</year><volume>9</volume><fpage>879</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">7232206</pub-id></element-citation></ref><ref id="b34-conc-17-s31"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conner</surname><given-names>BJ</given-names></name><name><surname>Reyes</surname><given-names>AA</given-names></name><name><surname>Morin</surname><given-names>C</given-names></name><etal/></person-group><article-title>Detection of sickle cell beta S-globin allele by hybridizationwith synthetic oligonucleotides. Proc Natl Acad Sci USA</article-title><source>PNAS</source><year>1983</year><volume>80</volume><fpage>278</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">6572002</pub-id></element-citation></ref><ref id="b35-conc-17-s31"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gundry</surname><given-names>CN</given-names></name><name><surname>Vandersteen</surname><given-names>JG</given-names></name><name><surname>Reed</surname><given-names>GH</given-names></name><etal/></person-group><article-title>Amplicon melting analysis with labeled primers: A closed-tube method for differentiating homozygotes and heterozygotes</article-title><source>Clin Chem</source><year>2003</year><volume>49</volume><fpage>396</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">12600951</pub-id></element-citation></ref><ref id="b36-conc-17-s31"><label>36.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>College of American Pathologists Perspectives on Emerging Technologies</collab></person-group><article-title>KRAS mutation testing for colorectal cancer</article-title><month>9</month><year>2009</year><ext-link ext-link-type="uri" xlink:href="http://www.cap.org/apps/docs/committees/technology/KRAS.pdf">http://www.cap.org/apps/docs/committees/technology/KRAS.pdf</ext-link> Accessed November 30, 2009.</mixed-citation></ref><ref id="b37-conc-17-s31"><label>37.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Juan</surname><given-names>T</given-names></name><name><surname>Suggs</surname><given-names>S</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name><etal/></person-group><article-title>A comparability study of 4 commercial KRAS tests [abstract #1811]</article-title><conf-name>American Association for Cancer Research (AACR) Annual Meeting</conf-name><conf-loc>San Diego, CA</conf-loc><conf-date>12&#x02013;16 April 2008</conf-date></element-citation></ref><ref id="b38-conc-17-s31"><label>38.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Shankaran</surname><given-names>V</given-names></name><name><surname>Bentrem</surname><given-names>DJ</given-names></name><name><surname>Mulcahy</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Economic implications of Kras testing in metastatic colorectal cancer (mCRC) [Abstract 298]</article-title><conf-name>2009 Gastrointestinal Cancers Symposium</conf-name><conf-loc>San Francisco, CA</conf-loc><conf-date>January 15&#x02013;17, 2009</conf-date></element-citation></ref><ref id="b39-conc-17-s31"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>Bondarenko</surname><given-names>I</given-names></name><name><surname>Makhson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>663</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">19114683</pub-id></element-citation></ref><ref id="b40-conc-17-s31"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benvenuti</surname><given-names>S</given-names></name><name><surname>Sartore-Bianchi</surname><given-names>A</given-names></name><name><surname>Di Nicolantonio</surname><given-names>F</given-names></name><etal/></person-group><article-title>Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>2643</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">17363584</pub-id></element-citation></ref><ref id="b41-conc-17-s31"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monzon</surname><given-names>FA</given-names></name><name><surname>Ogino</surname><given-names>S</given-names></name><name><surname>Hammond</surname><given-names>ME</given-names></name><etal/></person-group><article-title>The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer</article-title><source>Arch Pathol Lab Med</source><year>2009</year><volume>133</volume><fpage>1600</fpage><lpage>06</lpage><pub-id pub-id-type="pmid">19792050</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-conc-17-s31" position="float"><label>Figure 1</label><caption><p>Left: the EGFR pathway; Right: inhibition of the EGFR pathway by the EGFR monoclonal antibodies</p></caption><graphic xlink:href="conc-17-s31f1"/></fig><table-wrap id="t1-conc-17-s31" position="float"><label>Table I.</label><caption><p>Randomized clinical trial evidence on the relationship of KRAS mutation status to efficacy of anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="bottom" rowspan="2" colspan="1"/><th align="center" valign="bottom" rowspan="2" colspan="1"/><th align="center" valign="bottom" rowspan="2" colspan="1"/><th colspan="2" align="center" valign="bottom" rowspan="1"><bold><italic>KRAS</italic> Wild-type</bold></th><th colspan="2" align="center" valign="bottom" rowspan="1"><bold><italic>KRAS</italic> Mutated</bold></th></tr><tr><th align="center" valign="bottom" colspan="4" rowspan="1"><hr/></th></tr><tr><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>Study and Population</italic></th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>Treatments by Arm</italic></th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>Variable</italic></th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>Antibody Arm</italic></th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>Control Arm</italic></th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>Antibody Arm</italic></th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>Control Arm</italic></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">van Cutsem et al, 2008<xref ref-type="bibr" rid="b4-conc-17-s31">4</xref>; CRYSTAL trial of first-line therapy</td><td align="center" valign="top" rowspan="1" colspan="1">FOLFIRI &#x000b1; cetuximab</td><td align="center" valign="top" rowspan="1" colspan="1">n</td><td align="center" valign="top" rowspan="1" colspan="1">172</td><td align="center" valign="top" rowspan="1" colspan="1">176</td><td align="center" valign="top" rowspan="1" colspan="1">105</td><td align="center" valign="top" rowspan="1" colspan="1">87</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">RR (%)</td><td align="center" valign="top" rowspan="1" colspan="1">59.3</td><td align="center" valign="top" rowspan="1" colspan="1">43.2</td><td align="center" valign="top" rowspan="1" colspan="1">36.2</td><td align="center" valign="top" rowspan="1" colspan="1">40.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">95% CI</td><td align="center" valign="top" rowspan="1" colspan="1">51.6&#x02013;66.7</td><td align="center" valign="top" rowspan="1" colspan="1">35.8&#x02013;50.9</td><td align="center" valign="top" rowspan="1" colspan="1">27.0&#x02013;46.2</td><td align="center" valign="top" rowspan="1" colspan="1">29.9&#x02013;51.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">P</td><td colspan="2" align="center" valign="top" rowspan="1">0.0025</td><td colspan="2" align="center" valign="top" rowspan="1">0.46</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Median PFS (mo)</td><td align="center" valign="top" rowspan="1" colspan="1">9.9</td><td align="center" valign="top" rowspan="1" colspan="1">8.7</td><td align="center" valign="top" rowspan="1" colspan="1">7.6</td><td align="center" valign="top" rowspan="1" colspan="1">8.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">HR</td><td colspan="2" align="center" valign="top" rowspan="1">0.68</td><td colspan="2" align="center" valign="top" rowspan="1">1.07</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">P</td><td colspan="2" align="center" valign="top" rowspan="1">0.017</td><td colspan="2" align="center" valign="top" rowspan="1">0.47</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bokemeyer et al, 2009<xref ref-type="bibr" rid="b39-conc-17-s31">39</xref>; OPUS trial of first-line therapy</td><td align="center" valign="top" rowspan="1" colspan="1">FOLFOX - cetuximab</td><td align="center" valign="top" rowspan="1" colspan="1">n</td><td align="center" valign="top" rowspan="1" colspan="1">61</td><td align="center" valign="top" rowspan="1" colspan="1">73</td><td align="center" valign="top" rowspan="1" colspan="1">52</td><td align="center" valign="top" rowspan="1" colspan="1">47</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">RR (%)</td><td align="center" valign="top" rowspan="1" colspan="1">60.7</td><td align="center" valign="top" rowspan="1" colspan="1">37.0</td><td align="center" valign="top" rowspan="1" colspan="1">32.7</td><td align="center" valign="top" rowspan="1" colspan="1">48.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">95% CI</td><td align="center" valign="top" rowspan="1" colspan="1">47.3&#x02013;72.9</td><td align="center" valign="top" rowspan="1" colspan="1">26.0&#x02013;49.1</td><td align="center" valign="top" rowspan="1" colspan="1">20.3&#x02013;47.1</td><td align="center" valign="top" rowspan="1" colspan="1">34.1&#x02013;63.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">P</td><td colspan="2" align="center" valign="top" rowspan="1">0.011</td><td colspan="2" align="center" valign="top" rowspan="1">0.106</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">OR</td><td colspan="2" align="center" valign="top" rowspan="1">2.54</td><td colspan="2" align="center" valign="top" rowspan="1">0.51</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">95% CI</td><td colspan="2" align="center" valign="top" rowspan="1">1.24&#x02013;5.23</td><td colspan="2" align="center" valign="top" rowspan="1">0.22&#x02013;1.15</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Median PFS (mo)</td><td align="center" valign="top" rowspan="1" colspan="1">7.7</td><td align="center" valign="top" rowspan="1" colspan="1">7.2</td><td align="center" valign="top" rowspan="1" colspan="1">5.5</td><td align="center" valign="top" rowspan="1" colspan="1">8.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">HR</td><td colspan="2" align="center" valign="top" rowspan="1">0.57</td><td colspan="2" align="center" valign="top" rowspan="1">1.83</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">P</td><td colspan="2" align="center" valign="top" rowspan="1">0.016</td><td colspan="2" align="center" valign="top" rowspan="1">0.0192</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Punt et al, 2008<xref ref-type="bibr" rid="b11-conc-17-s31">11</xref>; CAIRO2 trial of first-line therapy</td><td align="center" valign="top" rowspan="1" colspan="1">(Capecitabine + oxaliplatin + bevacizumab) &#x000b1; cetuximab</td><td align="center" valign="top" rowspan="1" colspan="1">n</td><td align="center" valign="top" rowspan="1" colspan="1">153</td><td align="center" valign="top" rowspan="1" colspan="1">152</td><td align="center" valign="top" rowspan="1" colspan="1">93</td><td align="center" valign="top" rowspan="1" colspan="1">103</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Median PFS (mo)</td><td align="center" valign="top" rowspan="1" colspan="1">10.5</td><td align="center" valign="top" rowspan="1" colspan="1">10.7</td><td align="center" valign="top" rowspan="1" colspan="1">8.6</td><td align="center" valign="top" rowspan="1" colspan="1">12.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">P</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.43</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Median OS (mo)</td><td align="center" valign="top" rowspan="1" colspan="1">22.2</td><td align="center" valign="top" rowspan="1" colspan="1">23.0</td><td align="center" valign="top" rowspan="1" colspan="1">19.1</td><td align="center" valign="top" rowspan="1" colspan="1">24.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">P</td><td align="center" valign="top" rowspan="1" colspan="1">0.49</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.35</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Amado et al, 2008<xref ref-type="bibr" rid="b6-conc-17-s31">6</xref>; Chemotherapy-refractory disease</td><td align="center" valign="top" rowspan="1" colspan="1">Panitumumab <italic>v</italic> best supportive care</td><td align="center" valign="top" rowspan="1" colspan="1">n</td><td align="center" valign="top" rowspan="1" colspan="1">124</td><td align="center" valign="top" rowspan="1" colspan="1">119</td><td align="center" valign="top" rowspan="1" colspan="1">84</td><td align="center" valign="top" rowspan="1" colspan="1">100</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">RR (%)</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Median PFS (wks)</td><td align="center" valign="top" rowspan="1" colspan="1">12.3</td><td align="center" valign="top" rowspan="1" colspan="1">7.3</td><td align="center" valign="top" rowspan="1" colspan="1">7.4</td><td align="center" valign="top" rowspan="1" colspan="1">7.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">HR</td><td colspan="2" align="center" valign="top" rowspan="1">0.45</td><td colspan="2" align="center" valign="top" rowspan="1">0.99</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">95% CI</td><td colspan="2" align="center" valign="top" rowspan="1">0.34&#x02013;0.59</td><td colspan="2" align="center" valign="top" rowspan="1">0.73&#x02013;1.36</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Karapetis et al, 2008<xref ref-type="bibr" rid="b9-conc-17-s31">9</xref>; second- or subsequent-line therapy</td><td align="center" valign="top" rowspan="1" colspan="1">Cetuximab <italic>v</italic> best supportive care</td><td align="center" valign="top" rowspan="1" colspan="1">n</td><td align="center" valign="top" rowspan="1" colspan="1">117</td><td align="center" valign="top" rowspan="1" colspan="1">113</td><td align="center" valign="top" rowspan="1" colspan="1">81</td><td align="center" valign="top" rowspan="1" colspan="1">83</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">RR (%)</td><td align="center" valign="top" rowspan="1" colspan="1">12.8</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1.2</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Median PFS (mo)</td><td align="center" valign="top" rowspan="1" colspan="1">3.7</td><td align="center" valign="top" rowspan="1" colspan="1">1.9</td><td align="center" valign="top" rowspan="1" colspan="1">1.8</td><td align="center" valign="top" rowspan="1" colspan="1">1.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">HR</td><td colspan="2" align="center" valign="top" rowspan="1">0.40</td><td colspan="2" align="center" valign="top" rowspan="1">0.99</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">95% CI</td><td colspan="2" align="center" valign="top" rowspan="1">0.30&#x02013;0.54</td><td colspan="2" align="center" valign="top" rowspan="1">0.73&#x02013;1.36</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">P</td><td colspan="2" align="center" valign="top" rowspan="1">&#x0003c;0.001</td><td colspan="2" align="center" valign="top" rowspan="1">0.96</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Median OS (mo)</td><td align="center" valign="top" rowspan="1" colspan="1">9.5</td><td align="center" valign="top" rowspan="1" colspan="1">4.8</td><td align="center" valign="top" rowspan="1" colspan="1">4.5</td><td align="center" valign="top" rowspan="1" colspan="1">4.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">P</td><td colspan="4" align="center" valign="top" rowspan="1">0.01 (for interaction, <italic>KRAS</italic> mutation status and treatment arm)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">OS at 1 yr (%)</td><td align="center" valign="top" rowspan="1" colspan="1">28.3</td><td align="center" valign="top" rowspan="1" colspan="1">20.1</td><td align="center" valign="top" rowspan="1" colspan="1">13.2</td><td align="center" valign="top" rowspan="1" colspan="1">19.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">HR (death)</td><td colspan="2" align="center" valign="top" rowspan="1">0.55</td><td colspan="2" align="center" valign="top" rowspan="1">0.98</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">95% CI</td><td colspan="2" align="center" valign="top" rowspan="1">0.41&#x02013;0.74</td><td colspan="2" align="center" valign="top" rowspan="1">0.70&#x02013;1.37</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">P</td><td colspan="2" align="center" valign="top" rowspan="1">&#x0003c;0.001</td><td colspan="2" align="center" valign="top" rowspan="1">0.89</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-conc-17-s31"><p>EGFR = Epidermal growth factor receptor; HR = hazard ratio; OR = odds ratio; PFS = progression-free survival; FOLFIRI = folinic acid, fluorouracil, and irinotecan; FOLFOX = folinic acid, fluorouracil, and oxaliplatin; CRYSTAL = Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer; OPUS = Oxaliplatin and Cetuximab in First-Line Treatment of mCRC; CAIRO2, Capecitabine, Irinotecan, and Oxaliplatin in Advanced Colorectal Cancer; RR = Risk reduction</p></fn><fn id="tfn2-conc-17-s31"><p>Adapted with permission: BlueCross BlueShield Association. Technology Evaluation Center. KRAS Mutations and Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer TEC Assessments 2008; volume 23, tab 6. Copyright &#x000a9; 2008, BlueCross BlueShield Association.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-conc-17-s31" position="float"><label>Table II.</label><caption><p>Single-arm studies of treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies and KRAS mutational status</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>Study and Population</italic></th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>Treatments by Arm</italic></th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>Variable</italic></th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>KRAS Wild-type</italic></th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>KRAS Mutated</italic></th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Lievre et al, 2008<xref ref-type="bibr" rid="b10-conc-17-s31">10</xref>; second-line therapy</td><td align="center" valign="bottom" rowspan="1" colspan="1">Cetuximab</td><td align="center" valign="bottom" rowspan="1" colspan="1">n</td><td align="center" valign="bottom" rowspan="1" colspan="1">65</td><td align="center" valign="bottom" rowspan="1" colspan="1">24</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">RR</td><td align="center" valign="bottom" rowspan="1" colspan="1">40</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">P</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.001</td><td align="center" valign="bottom" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">PFS, weeks</td><td align="center" valign="bottom" rowspan="1" colspan="1">31.4</td><td align="center" valign="bottom" rowspan="1" colspan="1">10.1</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">95% CI</td><td align="center" valign="bottom" rowspan="1" colspan="1">19.4 to 36</td><td align="center" valign="bottom" rowspan="1" colspan="1">8 to 16</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">P</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.0001</td><td align="center" valign="bottom" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">OS, months</td><td align="center" valign="bottom" rowspan="1" colspan="1">14.3</td><td align="center" valign="bottom" rowspan="1" colspan="1">10.1</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">95% CI</td><td align="center" valign="bottom" rowspan="1" colspan="1">9.4 to 20</td><td align="center" valign="bottom" rowspan="1" colspan="1">5.1 to 13</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">P</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.026</td><td align="center" valign="bottom" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">De Roock et al, 2008<xref ref-type="bibr" rid="b8-conc-17-s31">8</xref></td><td align="center" valign="bottom" rowspan="1" colspan="1">Cetuximab alone v with irinotecan</td><td align="center" valign="bottom" rowspan="1" colspan="1">n</td><td align="center" valign="bottom" rowspan="1" colspan="1">57</td><td align="center" valign="bottom" rowspan="1" colspan="1">46</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">RR</td><td align="center" valign="bottom" rowspan="1" colspan="1">41</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">P (cetuximab vs. irinotecan)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.000001</td><td align="center" valign="bottom" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">P (cetuximab alone)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.126</td><td align="center" valign="bottom" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">PFS cetuximab vs. irinotecan (weeks)</td><td align="center" valign="bottom" rowspan="1" colspan="1">34</td><td align="center" valign="bottom" rowspan="1" colspan="1">12</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">95% CI</td><td align="center" valign="bottom" rowspan="1" colspan="1">28.5 to 40.0</td><td align="center" valign="bottom" rowspan="1" colspan="1">5.4 to 18.7</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">P</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.016</td><td align="center" valign="bottom" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">PFS cetuximab (weeks)</td><td align="center" valign="bottom" rowspan="1" colspan="1">12</td><td align="center" valign="bottom" rowspan="1" colspan="1">12</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">95% CI</td><td align="center" valign="bottom" rowspan="1" colspan="1">4.2 to 20.0</td><td align="center" valign="bottom" rowspan="1" colspan="1">7.0 to 17.0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">P</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.351</td><td align="center" valign="bottom" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">OS cetuximab. irinotecan (weeks)</td><td align="center" valign="bottom" rowspan="1" colspan="1">44.7</td><td align="center" valign="bottom" rowspan="1" colspan="1">27.3</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">95% CI</td><td align="center" valign="bottom" rowspan="1" colspan="1">28.4 to 61.0</td><td align="center" valign="bottom" rowspan="1" colspan="1">9.5 to 45.0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">P</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.003</td><td align="center" valign="bottom" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">OS (weeks)</td><td align="center" valign="bottom" rowspan="1" colspan="1">27</td><td align="center" valign="bottom" rowspan="1" colspan="1">25.3</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">95% CI</td><td align="center" valign="bottom" rowspan="1" colspan="1">8.9 to 45.1</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.0 to 70.0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">P</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.33</td><td align="center" valign="bottom" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Khambata-Ford et al, 2007<xref ref-type="bibr" rid="b7-conc-17-s31">7</xref></td><td align="center" valign="bottom" rowspan="1" colspan="1">Cetuximab; second-or third-line treatment</td><td align="center" valign="bottom" rowspan="1" colspan="1">n</td><td align="center" valign="bottom" rowspan="1" colspan="1">50</td><td align="center" valign="bottom" rowspan="1" colspan="1">30</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">RR (%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">10</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Di Fiore et al, 20077</td><td align="center" valign="bottom" rowspan="1" colspan="1">Cetuximab plus chemotherapy</td><td align="center" valign="bottom" rowspan="1" colspan="1">n</td><td align="center" valign="bottom" rowspan="1" colspan="1">43</td><td align="center" valign="bottom" rowspan="1" colspan="1">16</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1">RR (%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">28</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Benvenuti et al, 200740</td><td align="center" valign="top" rowspan="2" colspan="1">Panitumumab or cetuximab, or cetuximab plus chemotherapy</td><td align="center" valign="top" rowspan="1" colspan="1">n</td><td align="center" valign="top" rowspan="1" colspan="1">32</td><td align="center" valign="top" rowspan="1" colspan="1">16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">RR (%)</td><td align="center" valign="top" rowspan="1" colspan="1">31</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-conc-17-s31"><p>EGFR = epidermal growth factor receptor; PFS = progression-free survival; OS = overall survival.</p></fn><fn id="tfn4-conc-17-s31"><p>Adapted with permission: BlueCross BlueShield Association. Technology Evaluation Center. KRAS Mutations and Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer TEC Assessments 2008; volume 23, tab 6. Copyright &#x000a9; 2008, BlueCross BlueShield Association.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-conc-17-s31" position="float"><label>Table III.</label><caption><p>Methods for analyzing <italic>KRAS</italic> mutations<xref ref-type="bibr" rid="b22-conc-17-s31">22</xref>,<xref ref-type="bibr" rid="b41-conc-17-s31">41</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1"><italic>Method</italic></th><th align="center" valign="top" rowspan="1" colspan="1"><italic>Principle</italic></th><th align="center" valign="top" rowspan="1" colspan="1"><italic>Sensitivity (MT/WT, %)</italic></th><th align="center" valign="top" rowspan="1" colspan="1"><italic>Turnaround</italic></th><th align="center" valign="top" rowspan="1" colspan="1"><italic>Advantages</italic></th><th align="center" valign="top" rowspan="1" colspan="1"><italic>Disadvantages</italic></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Direct sequencing</td><td align="center" valign="top" rowspan="1" colspan="1">Non-mutation-specific determination of test case nucleotide sequence and comparison with normal sequence</td><td align="center" valign="top" rowspan="1" colspan="1">15&#x02013;25</td><td align="center" valign="top" rowspan="1" colspan="1">Slow (4 days to 2 weeks from paraffin)</td><td align="center" valign="top" rowspan="1" colspan="1">Gold standard<break/>Detects all possible mutations</td><td align="center" valign="top" rowspan="1" colspan="1">Poorly quantitative<break/>Insensitive; Labour intensive<break/>Open PCR system requires strict control to prevent contamination</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RFLP</td><td align="center" valign="top" rowspan="1" colspan="1">Mutation presence induces or eliminates specific sites where DNA-targeting enzymes insert cuts in DNA</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">Slow (4 days to 2 weeks from paraffin)</td><td align="center" valign="top" rowspan="1" colspan="1">Requires no specialized equipment, inexpensive</td><td align="center" valign="top" rowspan="1" colspan="1">Often requires confirmation by sequencing<break/>Does not identify specific mutation<break/>Non-quantitative</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Allele-specific probe</td><td align="center" valign="top" rowspan="1" colspan="1">Polymerase chain reaction/selective detection</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">Rapid (&#x0003c;2 days from paraffin)</td><td align="center" valign="top" rowspan="1" colspan="1">Rapid turnaround</td><td align="center" valign="top" rowspan="1" colspan="1">Relatively low sensitivity</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">High resolution melting analysis, confirmed by direct sequencing</td><td align="center" valign="top" rowspan="1" colspan="1">Sequences with mutations hybridize at different, fixed temperatures</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">Slow (4 days to 2 weeks from paraffin)</td><td align="center" valign="top" rowspan="1" colspan="1">Can screen for mutations prior to sequencing</td><td align="center" valign="top" rowspan="1" colspan="1">Complicated Requires sequencing confirmation<break/>Considerable manual input required</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Amplification refractory mutation system (ARMS)</td><td align="center" valign="top" rowspan="1" colspan="1">Mutation specific polymerase chain reaction/detection</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">Rapid (&#x0003c;2 days from paraffin)</td><td align="center" valign="top" rowspan="1" colspan="1">High sensitivity<break/>Rapid turnaround</td><td align="center" valign="top" rowspan="1" colspan="1">Detects only single specific mutation per reaction<break/>Requires specially engineered primer/probe</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TheraScreen&#x02122; KRAS testing kit (DxS, Manchester, United Kingdom)</td><td align="center" valign="top" rowspan="1" colspan="1">Combination of ARMS and real-time PCR technology</td><td align="center" valign="top" rowspan="1" colspan="1">1&#x02013;5%</td><td align="center" valign="top" rowspan="1" colspan="1">Rapid (2 days)</td><td align="center" valign="top" rowspan="1" colspan="1">High sensitivity<break/>Rapid turnaround<break/>Closed PCR system eliminates risk of contamination</td><td align="center" valign="top" rowspan="1" colspan="1">Detects only the most common mutations<break/>Requires more tissue for analysis than other methods<break/>Very Expensive</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Available as a commercial kit</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pyrosequencing</td><td align="center" valign="top" rowspan="1" colspan="1">Detection and measurement of the amount of pyrophosphate released by DNA extension reaction</td><td align="center" valign="top" rowspan="1" colspan="1">5&#x02013;10</td><td align="center" valign="top" rowspan="1" colspan="1">Rapid</td><td align="center" valign="top" rowspan="1" colspan="1">Precise and reproducible allele quantification<break/>Allows sequencing of relatively small PCR products (useful for degraded DNA samples).</td><td align="center" valign="top" rowspan="1" colspan="1">Short reading length for sequences used<break/>Open PCR system requires strict control to prevent contamination</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-conc-17-s31"><p>MT = Mutant; WT = Wild-type</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-conc-17-s31" position="float"><label>Table IV.</label><caption><p><italic>KRAS</italic> results of 8 mCRC tumor samples extracted from paraffin blocks: concordance among six testing laboratories</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="bottom" rowspan="1" colspan="1"/><th colspan="3" align="center" valign="bottom" rowspan="1"><italic>Reference Lab (Lab1)</italic><hr/></th><th align="center" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1"/></tr><tr><th align="center" valign="bottom" rowspan="2" colspan="1"><italic>Sample ID</italic></th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>DxS</italic></th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>Sequencing</italic></th><th align="center" valign="bottom" rowspan="1" colspan="1"><italic>FAM-labeled RFLP</italic></th><th align="center" valign="bottom" rowspan="2" colspan="1"><italic>Lab 2</italic></th><th align="center" valign="bottom" rowspan="2" colspan="1"><italic>Lab 3</italic></th><th align="center" valign="bottom" rowspan="2" colspan="1"><italic>Lab 4</italic></th><th align="center" valign="bottom" rowspan="2" colspan="1"><italic>Lab 5</italic></th><th align="center" valign="bottom" rowspan="2" colspan="1"><italic>Lab 6</italic></th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">Gly12Asp</td><td align="center" valign="top" rowspan="1" colspan="1">Gly12Asp</td><td align="center" valign="top" rowspan="1" colspan="1">Codon 12 +</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">Gly12Val</td><td align="center" valign="top" rowspan="1" colspan="1">Gly12Val</td><td align="center" valign="top" rowspan="1" colspan="1">Codon 12 +</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">Wild Type</td><td align="center" valign="top" rowspan="1" colspan="1">Wild Type</td><td align="center" valign="top" rowspan="1" colspan="1">Wild Type</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">RFLP:+ Seq: &#x02212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">Gly12Asp? &#x00394;ct 7.6</td><td align="center" valign="top" rowspan="1" colspan="1">Wild Type</td><td align="center" valign="top" rowspan="1" colspan="1">Codon 12 +? Low fluor</td><td align="center" valign="top" rowspan="1" colspan="1">wt</td><td align="center" valign="top" rowspan="1" colspan="1">wt</td><td align="center" valign="top" rowspan="1" colspan="1">wt</td><td align="center" valign="top" rowspan="1" colspan="1">wt</td><td align="center" valign="top" rowspan="1" colspan="1">DxS Gly12Asp? Seq: wt</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">Gly13Asp</td><td align="center" valign="top" rowspan="1" colspan="1">Gly13Asp</td><td align="center" valign="top" rowspan="1" colspan="1">Not Done</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">Wild Type</td><td align="center" valign="top" rowspan="1" colspan="1">Wild Type</td><td align="center" valign="top" rowspan="1" colspan="1">Wild Type</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">DxS: ? G13Asp</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">DxS: ? Seq: wt</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">Gly12Asp</td><td align="center" valign="top" rowspan="1" colspan="1">Gly12Asp</td><td align="center" valign="top" rowspan="1" colspan="1">Codon 12 +</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">Not Done</td><td align="center" valign="top" rowspan="1" colspan="1">Gly12Asp</td><td align="center" valign="top" rowspan="1" colspan="1">Codon 12 +</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0221a;</td><td align="center" valign="top" rowspan="1" colspan="1">Not determined</td><td align="center" valign="top" rowspan="1" colspan="1">Need to repeat</td><td align="center" valign="top" rowspan="1" colspan="1">RFLP: 12+ Seq: ?</td><td align="center" valign="top" rowspan="1" colspan="1">No tumor</td></tr></tbody></table></table-wrap></floats-group></article>